EMDMX-1 is under clinical development by Emyria and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase II drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EMDMX-1 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EMDMX-1 overview
EMDMX-1 are under development for the treatment of PTSD (drug-assisted psychotherapy). The drug candidates are psychedelic and MDMA analogues.
Emyria overview
Emyria, formerly Emerald Clinics, is a clinical-stage biotechnology company that discovers and develops therapies and treatments for unmet diseases. The company’s product pipeline includes CBD (Cannabinoid) medicines such as EMD-RX5, EMD-RX7 and EMD-RX9 capsules for treating psychological distress, chronic pain, autism and gut health conditions; and Methylenedioxymethamphetamine (MDMA) medicines for drug-assisted psychotherapy, Parkinson’s and fibrotic diseases. It also invests in data gathering and analysis through its proprietary smartphone monitoring application, Class IIA medical device, which discovers new clinical insights and guides drug development. Emyria works in collaboration with CMAX, Clinitrials, and the University of Western Australia (UWA) for clinical trials and drug development. It operates in Australia, the UK, and the US. Emyria is headquartered in Perth, Western Australia, Australia.
For a complete picture of EMDMX-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
